Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Palvella’s recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies

Read more at globenewswire.com